Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic
  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Cvergenx Inc. to Collaborate in Novel Approach to Personalized Radiotherapy and Drug Discovery

Predictive Oncology (NASDAQ: POAI) and Cvergenx today announced an agreement to form a strategic partnership that will potentially revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery. According to the announcement, the collaboration’s objective is to leverage and maximize the combined power of proprietary technologies and domain expertise. By applying Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities (“PEDAL”), and the Cvergenx precision genomics radiation therapy platform (“pGRT(TM)”), the two companies will pursue new ways in which to optimize radiotherapy (“RT”) to improve patient outcomes. “The central principle in precision medicine is that cancer therapy should be tailored to the individual tumor biology. Even so, radiation therapy, the most commonly utilized therapeutic agent in clinical oncology, has yet to enter the era of precision therapy,” said Raymond F. Vennare, CEO of Predictive Oncology. “We believe that the next and most significant paradigm shift in the field of radiation oncology will come from exploiting tumor genomics to optimize RT prescription dose and to identify drug targets for the development of radiosensitizers and radioprotectors for biopharma and industry.”

To view the full press release, visit https://ibn.fm/ZPkGD

About Predictive Oncology Inc.

As a science-driven company on the leading-edge of oncology drug discovery, Predictive Oncology offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world’s largest privately held biobank of over 150K tumor samples. Predictive Oncology’s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.